3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
35
Neoplasm Metastasis
10
Recurrence
7
Breast Neoplasms
5
Carcinoma, Transitional Cell
4
Stomach Neoplasms
3
Neoplastic Cells, Circulating
3
Metastatic Castration-resistant Prostate Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Ovarian Neoplasms
2
Neoplasms
2
Glioblastoma
2
Carcinoma, Squamous Cell
2
Thrombocytosis
1
Testicular Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer, Hereditary, 7
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Nonseminomatous germ cell tumor
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Interventions
Carboplatin
177
Radiotherapy
139
Cisplatin
110
Pemetrexed
102
Docetaxel
93
Paclitaxel
92
Gemcitabine
78
Erlotinib Hydrochloride
73
Magnetic Resonance Spectroscopy
72
Radiosurgery
67
Bevacizumab
65
pembrolizumab
64
Etoposide
60
Blood Specimen Collection
60
durvalumab
53
Specimen Handling
48
Nivolumab
48
Surveys and Questionnaires
47
Drug Therapy
41
Standard of Care
35
Radiation
33
osimertinib
32
atezolizumab
32
Surgical Procedures, Operative
30
Topotecan
29
Irinotecan
29
Gefitinib
29
Educational Status
29
Early Intervention, Educational
29
Biopsy
28
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lung Neoplasms
×
cabazitaxel
×
Clear all
NCT02166658
2018-01-23
CaBaMet
AIO-Studien-gGmbH
Phase 2
Terminated
8 enrolled